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RESULTS: The incidence of major bleeding among 4005 Medi-
care beneﬁciaries who underwent an incident surgery was 4.7%.
Patients experiencing major bleeding had longer hospital lengths
of stay (11.5 vs. 9.8 days, P < 0.01), longer ICU lengths of stay
(10 vs. 7.7 days, P < 0.01), were more likely to die in the hospital
(OR = 1.95, P < 0.01), and were responsible for signiﬁcantly
higher charges (+$18,512, P < 0.01) and reimbursements
(+$2642, P < 0.01). Over two years of follow-up, patients with
major bleeding were more likely to experience renal failure
(OR = 1.40, P = 0.06), were more likely to die (P < 0.01), and
incurred higher medical care costs (P < 0.05). CONCLUSION:
Patients who experienced major bleeding during CABG requiring
CPB tended to have poorer immediate and longer-term out-
comes. Results suggest that interventions to prevent major
bleeding during cardiac surgery may diminish or prevent these
negative clinical and economic outcomes.
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CANTWO A’S RESULT IN A FAILURE?: EFFECT OF ASPIRIN
ONTHE RISK OF HEART FAILURE HOSPITALIZATIONS IN
CHF PATIENTS ON ACE INHIBITORS
Shah DH, Parikh NM, Kamble PS, Chen H, Johnson M
University of Houston, Houston,TX, USA
OBJECTIVE: Aspirin use may negatively interact with the effect
of ACE inhibitors in treating heart failure. Hence, we sought to
determine whether aspirin increases the risk of heart failure
hospitalizations in non-elderly CHF patients on ACE Inhibitors.
METHODS: A retrospective analysis of the 2001 Georgia Med-
icaid claims data was performed. Patients between 18–64 years
of age who received a diagnosis of CHF (ICD-9 CM = 428.XX)
and ﬁlled at least one prescription for ACE Inhibitors between
January 1, 2001 and June 30, 2001 were included in the study.
Among these patients, those receiving aspirin were classiﬁed as
the exposed group and patients not receiving aspirin were clas-
siﬁed as the unexposed group. Hospitalization due to heart
failure was assessed between July 1, 2001 and December 31,
2001. Multi-variable logistic regression provided adjusted esti-
mates of the aspirin effect, with nonusers as the reference group,
after controlling for demographic factors, co-morbidities and
co-medications. RESULTS: One thousand four hundred fourteen
patients were identiﬁed. The total number of aspirin users was
178 (12.58%). Average age was 51.36 years and most patients
were females (66.5%). Also, most of the selected patients were
African Americans (57.1%). The unadjusted odds ratio for
exposure to aspirin was 1.798 (95% CI 1.097–2.896) and
the adjusted odds ratio was 1.782 (95% CI 1.074–3.009).
CONCLUSION: Aspirin use was associated with a greater risk
of hospitalization due to HF in patients taking ACE Inhibitors.
Hence, even in non-elderly CHF patients, a caution should be




REAL-WORLD SIX MONTH OUTCOMES OF PATIENTS
INITIATING EXENATIDE IN A PRIMARY CARE ELECTRONIC
MEDICAL RECORD DATABASE
Brixner D1, McAdam-Marx C1,Ye X1, Boye KS2, Schroeder B3,
Fabunmi R3
1The University of Utah College of Pharmacy, Salt Lake City, UT, USA,
2Eli Lilly and Company, Indianapolis, IN, USA, 3Amylin Pharmaceuticals,
Inc, San Diego, CA, USA
OBJECTIVE: This study evaluated real world outcomes of
A1C and weight in patients with type-2 diabetes (T2DM) ini-
tiating exenatide therapy. METHODS: Patient data were
extracted from the General Electric (GE) electronic medical
record (EMR) research database from January 1, 2000 through
September 30, 2007. Patients were 18 years old with T2DM
deﬁned by ICD-9 codes, 2 fasting blood glucose levels
126 mg/dL, or glycosylated hemoglobin (A1C) over 7.0%.
Patients had prescription orders in the previous 395 d for met-
formin (MET), a sulfonylurea (SU) or a thiazolidinedione
(TZD) as monotherapy or in combination. Baseline A1C,
weight and BMI were documented 45 d prior to 15 d post-
exenatide initiation and 45 d at 6 mo post-exenatide initia-
tion. RESULTS: For the 2086 patients with 6 mo of follow-up
data, baseline mean (SD) A1C was 8.4  1.2%, weight was
243.4  54.8 lbs and BMI was 38.5  7.9 kg/m2. Upon initia-
tion of exenatide, 363 (17.4%), 147 (7.1%) and 84 (4.0%)
were on MET, SU or TZD monotherapy respectively, 524
(25.1%) and 257 (12.3%) were on MET with TZD or SU, and
711 (34.1%) were on all three. Overall A1C change at 6 mo
(n = 878) was -0.7%. When exenatide was added to MET, SU
or TZD monotherapy, changes were -0.9% (p < 0.0001),
-1.0% (p < 0.0001) and -0.8% (p < 0.0032) respectively. A1C
lowering ranged from -0.5% to -0.8% with multiple oral
antidiabetic drugs (OADs) (p < 0.0001). Overall weight loss
(n = 1784) was -6.1 lbs (p < 0.0001). In the 6 mo following
addition of exenatide to prior monotherapy, 14%, 23% and
45% of patients discontinued MET, SU and TZD respectively.
Similar discontinuations were seen in the multiple OAD groups.
CONCLUSION: The average baseline A1C (8.4%) and BMI
(38.5 kg/m2) is high in this primary care T2DM population,
suggesting difﬁculty in the real world to achieve A1C and body
weight goals. Exenatide therapy demonstrated signiﬁcant reduc-
tions in A1C and weight over 6 mo with decreases in concomi-
tant medications.
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COST-EFFECTIVENESS ANALYSIS OF PREGABALIN FORTHE
MANAGEMENT OF NEUROPATHIC PAIN ASSOCIATEDWITH
DIABETIC PERIPHERAL NEUROPATHY IN MEXICO
Arreola-Ornelas H1, Dorantes-Aguilar J1, García-Mollinedo MDL2,
Rosado-Buzzo AA2, Mould-Quevedo J3, Davila-Loaiza G3
1Fundación Mexicana para la Salud, Funsalud, Mexico City, Mexico,
2Links & Links S.A. de C.V, Mexico City, Mexico, 3Pﬁzer Mexico,
Mexico City, Mexico
OBJECTIVE:Neuropathic pain is a chronic condition that causes
functional impairment in many areas of life and it occurs fre-
quently with diabetes. The aim of this study was to analyze the
cost-effectiveness of different treatments in managing diabetic
peripheral neuropathy from the health care payer’s perspective.
METHODS: A four-state stochastic Markov model was per-
formed to estimate costs and effectiveness. The Markov model
includes several stages related to functional disability (mild-pain,
moderate-pain, severe-pain and death). Effectivenesswas assumed
as the percentage of patients with no or mild pain (pain score <4)
at the end of the follow-up period (one-year).Transition probabili-
ties were taken from national and international published litera-
ture. Comparators used in the assessment were carbamazepine
(200–600 mg/day), amitriptyline (100–150 mg/day), gabapen-
tin (2400–3600 mg/day) and pregabalin (300–600 mg/day).
Resource use and costs were obtained from hospital records
(n = 1000) from the Social Security Mexican Institute (IMSS)
and ofﬁcial institutional databases. Costs include emergency, out-
patient and inpatient services, drugs, procedures, etc. The model
was calibrated. Probabilistic sensitivity analyses were performed
employing bootstrapping techniques and acceptability curves
were constructed. RESULTS: The highest percentage of patients
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with no or mild pain during the follow-up period was obtained by
pregabalin (59.6%;CI95% 59.0%–60.2%); followed by gabap-
entin (49.2%; CI95% 48.7%–49.7%); amitriptyline (47.6%;
CI95% 47.1%–48.1%) and carbamazepine (34.4%; CI95%
34.1%–34.8%). The annual expected mean costs per patient
were US$3001.4 (CI95% US$2956.4–US$3046.3); US$4,707.7
(CI95% US$4689.9–US$4723.6); US$2814.4 (CI95%
US$2783.4–US$2845.5) and US$3701.9 (CI95% US$3687.2–
US$3716.6); respectively following the order above. The ICER’s
of pregabalin vs. carbamazepine (baseline), gabapentin and
amitriptyline were -US$700.5 (CI95% -US$670.4:-US$730.7),
-US$1706.4 (CI95% -US$1677.3:-US$1733.4) and US$186.9
(CI95% US$173.1–US$200.8); respectively. Using acceptability
curves (WTP US$5000–US$50,000), pregabalin showed a prob-
ability between 90–99% to be the treatment most cost-effective.
CONCLUSION: In Mexico, pregabalin showed to be a cost-
saving therapy when is compared with carbamazepine and gaba-
pentin; and cost-effective vs. amitriptyline in the management of
neuropathic pain.
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REAL-WORLD ANALYSIS OF PERCENT OF PATIENTSWITH
TYPE 2 DIABETES ACHIEVING GLYCEMIC GOALWITH
INSULIN GLARGINE
Misurski D1, Schroeder B2,Wade R3, Quimbo R3, Nielsen L2,
Fabunmi R2,Wintle M2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Amylin Pharmaceuticals,
Inc, San Diego, CA, USA, 3HealthCore, Inc,Wilmington, DE, USA
OBJECTIVE: The primary aim of type 2 diabetes (T2D) therapy
is helping patients achieve glycemic goals (A1C < 7%) as recom-
mended by the ADA. In the recent randomized controlled trials
4-T and INITIATE, patients treated with basal insulin alone
achieved goal 28% and 40% of the time, respectively, despite
progressive insulin titration. In this retrospective cohort study
using a large, US commercial health plan claims database, we
describe the clinical effectiveness of newly-prescribed basal
insulin glargine (IG) in insulin-naive patients. METHODS: A
total of 13,154 insulin-naïve (not prescribed insulin in previous
6 mo) patients were identiﬁed with a new prescription claim for
IG between January 1, 2004 and June 30, 2006, 6 mo of
pre-index eligibility (ﬁrst claim = index date), 12 mo of post-
index eligibility, and 18 y old. RESULTS: From this cohort,
7730 (59%) patients had no other insulin claims other than IG in
the entire post-index period. All patients with baseline (100 d
pre-index) and post-index (60–365 d) A1C data available and
baseline A1C7.0% were analyzed (n = 313; mean baseline A1C
(SD) = 9.8  2.1%). Mean (SD) age was 52  8 y (41%
female; 3%65 y). In this cohort of patients who did not add
any additional insulin (n = 313), 27% achieved A1C < 7% in the
post-index period (mean [min,max] time index to post-index
A1C = 238 d [63,365]). Mean (SD) post-index A1C was
8.2  1.9%. CONCLUSION: In this real-world analysis of
patients initiated on IG, the percentage of patients achieving
A1C < 7.0% and mean post-index A1C indicate that most
patients do not achieve recommended glycemic targets—results
which mirror controlled clinical studies. In addition, more than
half of patients initiating IG did not supplement with additional
insulin therapy over the course of the ﬁrst year of therapy, despite
not reaching glycemic goals. Because the contribution of post-
prandial glucose to A1C increases as A1C approaches goal,
agents targeting fasting glucose alone, like IG, may be insufﬁcient
in helping patients with T2D achieve glycemic goals.
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RETROSPECTIVE STUDY OFTYPE 2 DIABETES MELLITUS
(T2DM) PATIENTS NOT OPTIMALLY CONTROLLED BY
METFORMIN MONOTHERAPY
He J, Neslusan C
Johnson & Johnson Pharmaceutical Services L.L.C, Raritan, NJ, USA
OBJECTIVE: The American Diabetes Association (ADA) recom-
mends metformin as ﬁrst line treatment for T2DM. As diabetes is
a progressive disease, patients will ultimately need additional
therapies to reach glycemic goals. Little information has been
published that describes what happens to patients not optimally
controlled on metformin monotherapy in the real world. We
analyzed monitoring, treatments and outcomes for such patients
using the PHARMetrics® linked laboratory database.
METHODS: An algorithm based on ICD-9 codes and laboratory
test values identiﬁed 1901 T2DM patients who failed metformin
monotherapy between 2000 and 2006. The index date was
deﬁned as the ﬁrst Hba1c test greater than the ADA recom-
mended goal of 7%, after at least 6 months metformin mono-
therapy. The pre-period was deﬁned as two years prior to the
index date. The follow-up period was deﬁned as 12 months after
the index date. Other laboratory test values were obtained during
a +/-30-day window of the index date. Micro- and macro-
vascular diabetes-related complications were identiﬁed using
ICD-9 codes during the pre-period. Subsequent glucose control
and ﬁrst therapy change in the 3 to 12 months of the follow-up
period were also analyzed. RESULTS: A total of 48.5% of the
sample was male. Mean age was 57.9 (11). The prevalence of
diabetic-related complications were as follows: retinopathy
(12.64%); neuropathy (12.13%); nephropathy (2.67%); myo-
cardial infarction (1.31%); stroke (2.82%) and ischemic heart
disease (12.99%). In the follow-up period, 76.5% of patients had
an Hba1c test and only 24.7% were at goal. Only 33% changed
therapy: 19% added on sulfonylurea; 5% switched to a ﬁxed-
dose combination product and 4% added or switched to thiazo-
lidinedione. Overall, the average time from failure until therapy
change was 256.0 days (73.1). CONCLUSION: These results
indicate considerable unmet medical need in treating T2DM.
Glycemic control would have likely been better with additional
pharmaceutical utilization.
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DEMOGRAPHIC RISK FACTORS FOR STROKE RELATED
AMBULATORY CARE UTILIZATION:ANALYSIS OF UNITED
STATES NATIONAL DATA 2000–2005
Karve S, Levine D, Balkrishnan R
The Ohio State University, Columbus, OH, USA
OBJECTIVE: To assess age, racial, and regional differences in
utilization of physician, hospital outpatient and emergency
department services related to stroke over the past six years.
METHODS: This study was a retrospective analysis of the
National Ambulatory Medical Care Survey (NAMCS) and the
National Hospital Ambulatory Medical Care Survey (NHAMCS)
from 2000..C2005. Ischemic stroke related visits in persons aged
45 years were identiﬁed using diagnosis codes (ICD 9 CM)
433.1x, 434.xx, and 436.xx. Visits per/1000 persons were calcu-
lated using United States population estimates. With logistic
regression, we adjusted associations between stroke-related visits
and age, race, and region (Northeast, Midwest, West, and South),
for sex, stroke risk factors, insurance type, and survey year.
RESULTS: From 2000 to 2005, stroke-related ambulatory care
visits increased signiﬁcantly from 8.3/1000 persons to 16.1/1000
persons (P Trend=<0.0001)..Crepresenting a 195% rise in stroke
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